Contribution: Industrial Research Assistance Program – Contributions to Firms
J2 SCIENCE INC.
$75,000.00
Enhancing Cannabinoid Efficacy via Nano-Encapsulation: Improving Stability, Bio-Absorption, and Physiological Effects
EF 2025-26 · 2025-11-10
Résumé
The project will apply a nano-encapsulation to CBD, CBG, and CBN to assess stability and absorption using a simulated gastrointestinal model. The goal is to enhance taste, formulation stability, and bioavailability, achieving more consistent performance than conventional ingestible products.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Chateauguay|Châteauguay, Quebec, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
750990699
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Agreement End Date
2026-07-03
Agreement Number
1037906
Agreement Start Date
2025-11-10
Agreement Title
Enhancing Cannabinoid Efficacy via Nano-Encapsulation: Improving Stability, Bio-Absorption, and Physiological Effects
Agreement Title (French)
Améliorer l’efficacité des cannabinoïdes grâce à la nano-encapsulation : améliorer la stabilité, la bioabsorption et les effets physiologiques
Agreement Type
Contribution
Agreement Value
$75,000.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The project will apply a nano-encapsulation to CBD, CBG, and CBN to assess stability and absorption using a simulated gastrointestinal model. The goal is to enhance taste, formulation stability, and bioavailability, achieving more consistent performance than conventional ingestible products.
Description (French)
Le projet appliquera une nano-encapsulation au CBD, au CBG et au CBN afin d’évaluer la stabilité et l’absorption à l’aide d’un modèle gastro-intestinal simulé. L’objectif est d’améliorer le goût, la stabilité de la formulation et la biodisponibilité, afin d’obtenir des performances plus constantes que les produits ingérables conventionnels.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Châteauguay--Lacolle
Federal Riding (French)
Châteauguay--Lacolle
Federal Riding Number
24021
NAICS Code
31231
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
750990699
Recipient City
Chateauguay|Châteauguay
Recipient Country
CA
Recipient Legal Name
J2 SCIENCE INC.
Recipient Postal Code
J6J 4Z2
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2025-2026-Q3-1037906
